Floatz logo

Rpm Cd19-Mbil15-Car-T Cells

Non-Hodgkin's Lymphoma Refractory

Eden BioCell Ltd.Cell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Non-Hodgkin's Lymphoma Refractory cohort.

Asset / SponsorPhaseRating
Autologous Car19 T Lymphocytes
Institute of Hematology and Blood Transfusion, Czech Republic
Phase 1CC
cd19/bcma-targeted car-t cells
Zhejiang University
Early Phase 1C

Same molecule, other indications

Rpm Cd19-Mbil15-Car-T Cells is also rated in:

non-Hodgkin lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
CC
Indicative ·
41 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →